▶ 調査レポート

生物製剤受託製造の世界市場

• 英文タイトル:Global Market Study on Biologics Contract Manufacturing Demand: Strong Biologics Pipeline to Rapidly Surge Market Growth

Persistence Market Researchが調査・発行した産業分析レポートです。生物製剤受託製造の世界市場 / Global Market Study on Biologics Contract Manufacturing Demand: Strong Biologics Pipeline to Rapidly Surge Market Growth / PMR201205資料のイメージです。• レポートコード:PMR201205
• 出版社/出版日:Persistence Market Research / 2020年9月25日
• レポート形態:英文、PDF、293ページ
• 納品方法:Eメール
• 産業分類:生命科学
• 販売価格(消費税別)
  Single User¥725,200 (USD4,900)▷ お問い合わせ
  Site Licence¥1,124,800 (USD7,600)▷ お問い合わせ
  Enterprisewide¥1,568,800 (USD10,600)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本調査レポートでは生物製剤受託製造の世界市場について調査・分析し、エグゼクティブサマリー、市場概要、主要市場動向、市場背景、新型コロナウイルス感染症の危機影響分析、市場動向、需要分析・予測、価格分析、製品別(成長因子、インターフェロン、モノクローナル抗体、組換えホルモン、 ワクチン)、プラットホーム別(哺乳類、微生物)、治療領域別(自己免疫疾患、腫瘍学、代謝性疾患、眼科、心血管疾患)、用途別(臨床、商業)、地域別分析、市場構造分析、競争分析、仮定、調査手法などの項目を掲載しています。
・エグゼクティブサマリー
・市場概要
・主要市場動向
・市場背景
・新型コロナウイルス感染症の危機影響分析
・市場動向
・需要分析・予測
・価格分析
・生物製剤受託製造の世界市場規模:製品別(成長因子、インターフェロン、モノクローナル抗体、組換えホルモン、 ワクチン)
・生物製剤受託製造の世界市場規模:プラットホーム別(哺乳類、微生物)
・生物製剤受託製造の世界市場規模:治療領域別(自己免疫疾患、腫瘍学、代謝性疾患、眼科、心血管疾患)
・生物製剤受託製造の世界市場規模:用途別(臨床、商業)
・生物製剤受託製造の世界市場規模:地域別
・市場構造分析
・競争分析
・仮定
・調査手法

Biologics Contract Manufacturing Demand – Scope of the Report

Persistence Market Research (PMR) recently published a market study on the global market for biologics contract manufacturing demand. The study provides detailed assessment on key market dynamics, including the drivers, trends, opportunities, restraints, and detailed information about the biologics contract manufacturing demand structure. The market study presents exclusive information about how biologics contract manufacturing demand will grow during the forecast period of 2020-2030.

Key indicators of market growth, which include Year-on-Year (Y-o-Y) growth of the market, and compounded annual growth rate (CAGR) are explained in PMR’s study in a comprehensive manner. This information can help readers understand the quantitative growth prospects of biologics contract manufacturing demand during the forecast period.

The study is relevant for stakeholders interested in biologics contract manufacturing demand, including biologics contract manufacturing service organizations, suppliers, distributors, and investors, and can help them in developing appropriate strategies to grow in the market. Stakeholders in biologics contract manufacturing demand, investors, industry experts, researchers, and journalists, as well as business researchers can leverage the information and data presented in PMR’s study.

The study also includes statistics as well as facts related to the macro- as well as micro-economic factors that are impacting developments in the market. It also offers actionable insights based on the future trends regarding biologics contract manufacturing demand. Furthermore, small businesses and new entrants related to biologics contract manufacturing demand too can make use of the information presented in this study, based on which, they can make appropriate business decisions to gain momentum in the market.

Key Questions Answered in PMR’s Biologics Contract Manufacturing Demand Study

How will CDMO services demand unfold over the coming years?
Which regions will continue to remain the most profitable regional markets for players dealing with biologics contract manufacturing demand?
Which factors will induce a change in biologics contract manufacturing demand during the assessment period?
How will changing trends impact biologics contract manufacturing demand?
How can market players capture the low-hanging opportunities related to biologics contract manufacturing demand in developed regions?
Which companies are leading in biologics contract manufacturing demand?
What are the winning strategies of stakeholders involved in biologics contract manufacturing demand services to upscale their position in this landscape?
Biologics Contract Manufacturing Demand: Research Methodology

In PMR’s study, a unique research methodology is utilized to conduct extensive research on the growth of biologics contract manufacturing demand, and reach conclusions on the future growth parameters of the market. This research methodology is a combination of primary and secondary research, which helps analysts ensure the accuracy and reliability of the conclusions.

Secondary resources referred to by analysts during the production of the biologics contract manufacturing demand market study include statistics from government organizations, trade journals, white papers, and internal and external proprietary databases. Analysts have interviewed senior managers, product portfolio managers, CEOs, VPs, marketing/product managers, and market intelligence managers, who contributed to the development of this report as a primary resource.

Comprehensive information acquired from primary and secondary resources acts as a validation from companies dealing in biologics contract manufacturing demand, and makes PMR’s projections on the growth prospects of the market space more accurate and reliable.

レポート目次

1. Executive Summary

1.1. Global Market Outlook

1.2. Demand Side Trends

1.3. Supply Side Trends

1.4. Competitive Snapshot, Capacity (kL)

1.5. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy

2.2. Market Definition / Scope / Limitations

3. Key Market Trends

3.1. Key Trends Impacting The Market

3.2. Product Development Trends

4. Market Background

4.1. Macro-Economic Factors

4.1.1. Global GDP Growth Outlook

4.1.2. Global Healthcare Expenditure Outlook

4.1.3. Growth of Healthcare Sector in Emerging Nations

4.2. Forecast Factors – Relevance & Impact

4.2.1. Global Increase in Healthcare Expenditure

4.2.2. Strong biologics pipeline fuel demand for the CMOs

4.2.3. Corporate Venture Capital Investments are Helping Advance Biotechnology R&D

4.2.4. Changing regulatory dynamics are hampering the growth of Biopharmaceutical contract manufacturing market

4.2.5. CMO Cost Impact

4.2.6. Regulatory Scenario

4.3. Market Dynamics

4.3.1. Drivers

4.3.2. Restraints

4.3.3. Opportunity Analysis

5. COVID19 Crisis Impact Analysis

5.1. COVID19 Crisis Impact Analysis

5.1.1. Current COVID19 Statistics and Probable Future Impact

5.1.2. Current GDP Projection and Probable Impact

5.1.3. Current Economic Projection as compared to 2008 Economic analysis

5.1.4. COVID19 and Impact Analysis

5.2. Biopharmaceutical Contract Manufacturing Market Capacity Analysis

5.2.1. Historical (pre-COVID), Current (during-COVID), Future (post-COVID)

5.2.1.1. By Product

5.2.1.2. By Therapeutic Area

5.2.1.3. By Platform

5.2.1.4. By Application

5.2.1.5. By Region (including especially EU/U.K./U.S.)

5.2.2. Manufacturing Capacity Expansion for COVID-19 Related Products

5.3. Biopharmaceutical Contract Manufacturing Market Demand Analysis

5.3.1. Historical (pre-COVID), Current (during-COVID), Future (post-COVID)

5.3.1.1. By Product

5.3.1.2. By Therapeutic Area

5.3.1.3. By Platform

5.3.1.4. By Application

5.3.1.5. By Region (including especially EU/U.K./U.S.)

5.3.2. Covid-19 Impact Pricing Analysis

5.3.2.1. Historical (pre-COVID), Current (during-COVID), Future (post-COVID)

5.3.3. Capacity Utilization Analysis

5.3.3.1. Initiation of COVID-19 related Products Contract Manufacturing

5.3.3.2. Timeframe of Capacity and Slot Utilization for COVID-related Products

5.3.4. 2020 Market Scenario

5.3.5. Quarter by Quarter Forecast

5.3.6. Projected Recovery Quarter

5.4. Impact on Trends Analysis

5.4.1. Single-Use

5.4.2. Modular

5.4.3. Consolidation

5.5. Recovery Scenario – Short term, Midterm and Long Term Impact

6. Market Context

6.1. Product Adoption / Usage Analysis

6.2. Promotional Strategies by Key Players

6.3. Key Industry Deals

6.4. Regulatory Scenario

7. Global Biopharmaceutical Contract Manufacturing Market Capacity (in kL/Units) Analysis 2015-2019 and Forecast, 2020–2030

7.1. Historical Market Capacity (in kL/Units) Analysis, 2015-2019

7.2. Current and Future Market Capacity (kL/Units) Projections, 2020-2030

7.2.1. Y-o-Y Growth Trend Analysis

7.2.2. Absolute Capacity (in kL/Units) Opportunity Analysis

8. Global Biopharmaceutical Contract Manufacturing Market – Pricing Analysis

8.1. Regional Pricing Analysis, By Services

8.2. Global Average Pricing Analysis Benchmark

9. Global Biopharmaceutical Contract Manufacturing Market Demand (in Value or Size in US$ Mn) Analysis 2015-2019 and Forecast, 2020–2030

9.1. Historical Market Value (US$ Mn) Analysis, 2015-2019

9.2. Current and Future Market Value (US$ Mn) Projections, 2020-2030

9.2.1. Y-o-Y Growth Trend Analysis

9.2.2. Absolute $ Opportunity Analysis

10. Global Biopharmaceutical Contract Manufacturing Capacity Analysis 2015-2019 and Forecast 2020-2030, by Product

10.1. Introduction / Key Findings

10.2. Historical Market Capacity (in kL) Analysis By Product, 2015 – 2019

10.3. Current and Future Market Capacity (in kL) Analysis and Forecast By Product, 2020 – 2030

10.3.1. Growth Factors

10.3.2. Interferons

10.3.3. Monoclonal Antibodies

10.3.4. Recombinant Hormones

10.3.5. Vaccines

10.3.6. Insulin

10.3.7. Others

10.4. Market Attractiveness Analysis By Product

11. Global Biopharmaceutical Contract Manufacturing Capacity Analysis 2015-2019 and Forecast 2020-2030, By Platform

11.1. Introduction / Key Findings

11.2. Historical Market Capacity (in kL) Analysis By Platform, 2015 – 2019

11.3. Current and Future Market Capacity (in kL) Analysis and Forecast By Platform, 2020 – 2030

11.3.1. Mammalian

11.3.2. Microbial

11.4. Market Attractiveness Analysis By Platform

12. Global Biopharmaceutical Contract Manufacturing Capacity Analysis 2015-2019 and Forecast 2020-2030, By Therapeutic Area

12.1. Introduction / Key Findings

12.2. Historical Market Capacity (in kL) Analysis By Therapeutic Area, 2015 – 2019

12.3. Current and Future Market Capacity (in kL) Analysis and Forecast By Therapeutic Area, 2020 – 2030

12.3.1. Autoimmune Diseases

12.3.2. Oncology

12.3.3. Metabolic Diseases

12.3.4. Ophthalmology

12.3.5. Cardiovascular Diseases

12.3.6. Infectious Diseases

12.3.7. Neurology

12.3.8. Respiratory Disorders

12.3.9. Others

12.4. Market Attractiveness Analysis By Therapeutic Area

13. Global Biopharmaceutical Contract Manufacturing Capacity Analysis 2015-2019 and Forecast 2020-2030, By Application

13.1. Introduction / Key Findings

13.2. Historical Market Capacity (in kL) Analysis By Application, 2015 – 2019

13.3. Current and Future Market Capacity (in kL) Analysis and Forecast By Application, 2020 – 2030

13.3.1. Clinical

13.3.2. Commercial

13.4. Market Attractiveness Analysis By Application

14. Global Biopharmaceutical Contract Manufacturing Capacity Analysis 2015-2019 and Forecast 2020-2030, by Region

14.1. Introduction

14.2. Historical Market Capacity (in kL) Analysis By Region, 2015 – 2019

14.3. Current Market Capacity (in kL) Analysis and Forecast By Region, 2020 – 2030

14.3.1. North America

14.3.2. Latin America

14.3.3. Europe

14.3.4. East Asia

14.3.5. South Asia

14.3.6. Oceania

14.3.7. Middle East and Africa (MEA)

14.4. Market Attractiveness Analysis By Region

15. North America Biopharmaceutical Contract Manufacturing Demand Analysis 2015-2019 and Forecast 2020-2030

15.1. Introduction

15.2. Historical Market Capacity (in kL) Trend Analysis By Taxonomy, 2015 – 2019

15.3. Market Capacity (in kL) Forecast By Taxonomy, 2020 – 2030

15.3.1. By Country

15.3.1.1. U.S.

15.3.1.2. Canada

15.3.2. By Product

15.3.3. By Platform

15.3.4. By Therapeutic Area

15.3.5. By Application

15.4. Market Attractiveness Analysis

16. Latin America Biopharmaceutical Contract Manufacturing Demand Analysis 2015-2019 and Forecast 2020-2030

16.1. Introduction

16.2. Historical Market Capacity (in kL) Trend Analysis By Taxonomy, 2015 – 2019

16.3. Market Size Capacity (in kL) Forecast By Taxonomy, 2020 – 2030

16.3.1. By Country

16.3.1.1. Brazil

16.3.1.2. Mexico

16.3.1.3. Argentina

16.3.1.4. Rest of Latin America

16.3.2. By Product

16.3.3. By Platform

16.3.4. By Therapeutic Area

16.3.5. By Application

16.4. Market Attractiveness Analysis

17. Europe Biopharmaceutical Contract Manufacturing Demand Analysis 2015-2019 and Forecast 2020-2030

17.1. Introduction

17.2. Historical Market Capacity (in kL) Trend Analysis By Taxonomy, 2015 – 2019

17.3. Market Capacity (in kL) Forecast By Market, 2020 – 2030

17.3.1. By Country

17.3.1.1. Germany

17.3.1.2. Italy

17.3.1.3. France

17.3.1.4. U.K.

17.3.1.5. Spain

17.3.1.6. BENELUX

17.3.1.7. Russia

17.3.1.8. Rest of Europe

17.3.2. By Product

17.3.3. By Platform

17.3.4. By Therapeutic Area

17.3.5. By Application

17.4. Market Attractiveness Analysis

18. South Asia Biopharmaceutical Contract Manufacturing Demand Analysis 2015-2019 and Forecast 2020-2030

18.1. Introduction

18.2. Historical Market Capacity (in kL) Trend Analysis By Taxonomy, 2015 – 2019

18.3. Market Capacity (in kL) Forecast By Taxonomy, 2020 – 2030

18.3.1. By Country

18.3.1.1. India

18.3.1.2. Thailand

18.3.1.3. Indonesia

18.3.1.4. Malaysia

18.3.1.5. Rest of South Asia

18.3.2. By Product

18.3.3. By Platform

18.3.4. By Therapeutic Area

18.3.5. By Application

18.4. Market Attractiveness Analysis

19. East Asia Biopharmaceutical Contract Manufacturing Demand Analysis 2015-2019 and Forecast 2020-2030

19.1. Introduction

19.2. Historical Market Capacity (in kL) Trend Analysis By Taxonomy, 2015 – 2019

19.3. Market Size Capacity (in kL) Forecast By Taxonomy, 2020 – 2030

19.3.1. By Country

19.3.1.1. China

19.3.1.2. Japan

19.3.1.3. South Korea

19.3.2. By Product

19.3.3. By Platform

19.3.4. By Therapeutic Area

19.3.5. By Application

19.4. Market Attractiveness Analysis

20. Oceania Biopharmaceutical Contract Manufacturing Demand Analysis 2015-2019 and Forecast 2020-2030

20.1. Introduction

20.2. Historical Market Capacity (in kL) Trend Analysis By Taxonomy, 2015 – 2019

20.3. Market Capacity (in kL) Forecast By Taxonomy, 2020 – 2030

20.3.1. By Country

20.3.1.1. Australia

20.3.1.2. New Zealand

20.3.2. By Product

20.3.3. By Platform

20.3.4. By Therapeutic Area

20.3.5. By Application

20.4. Market Attractiveness Analysis

21. Middle East and Africa Biopharmaceutical Contract Manufacturing Demand Analysis 2015-2019 and Forecast 2020-2030

21.1. Introduction

21.2. Historical Market Capacity (in kL) Trend Analysis By Taxonomy, 2015 – 2019

21.3. Market Capacity (in kL) Forecast By Taxonomy, 2020 – 2030

21.3.1. By Country

21.3.1.1. GCC Countries

21.3.1.2. South Africa

21.3.1.3. Rest of Middle East and Africa

21.3.2. By Product

21.3.3. By Platform

21.3.4. By Therapeutic Area

21.3.5. By Application

21.4. Market Attractiveness Analysis

22. Key and Emerging Countries Biopharmaceutical Contract Manufacturing Demand Analysis 2015-2019 and Forecast 2020-2030

22.1. U.S. Biopharmaceutical Contract Manufacturing Demand Analysis

22.1.1. By Product

22.1.2. By Platform

22.1.3. By Therapeutic Area

22.1.4. By Application

22.2. Canada Biopharmaceutical Contract Manufacturing Demand Analysis

22.2.1. By Product

22.2.2. By Platform

22.2.3. By Therapeutic Area

22.2.4. By Application

22.3. U.K. Biopharmaceutical Contract Manufacturing Demand Analysis

22.3.1. By Product

22.3.2. By Platform

22.3.3. By Therapeutic Area

22.3.4. By Application

22.4. Germany Biopharmaceutical Contract Manufacturing Demand Analysis

22.4.1. By Product

22.4.2. By Platform

22.4.3. By Therapeutic Area

22.4.4. By Application

22.5. France Biopharmaceutical Contract Manufacturing Demand Analysis

22.5.1. By Product

22.5.2. By Platform

22.5.3. By Therapeutic Area

22.5.4. By Application

22.6. Spain Biopharmaceutical Contract Manufacturing Demand Analysis

22.6.1. By Product

22.6.2. By Platform

22.6.3. By Therapeutic Area

22.6.4. By Application

22.7. Italy Biopharmaceutical Contract Manufacturing Demand Analysis

22.7.1. By Product

22.7.2. By Platform

22.7.3. By Therapeutic Area

22.7.4. By Application

23. Market Structure Analysis

23.1. Market Analysis by Tier of Companies

23.2. Market Share Analysis of Top Players

23.3. Market Concentration

23.4. Market Presence Analysis

23.4.1. By Regional Footprint of Players

23.4.2. Product Footprint by Players

23.4.3. Channel Footprint by Players

24. Competition Analysis

24.1. Competition Dashboard

24.2. CDMO Capability & Capacity Analysis 2020

24.3. Competition Deep Dive

24.3.1. BioXcellence (Boehringer Ingelheim GmbH)

24.3.1.1. Overview

24.3.1.2. Product Portfolio

24.3.1.3. Key Financial

24.3.1.4. Sales Footprint

24.3.1.5. Analyst commentary

24.3.2. Lonza Group AG

24.3.2.1. Overview

24.3.2.2. Product Portfolio

24.3.2.3. Key Financial

24.3.2.4. Sales Footprint

24.3.2.5. Analyst commentary

24.3.3. Samsung Biologics Co. Ltd.

24.3.3.1. Overview

24.3.3.2. Product Portfolio

24.3.3.3. Key Financial

24.3.3.4. Sales Footprint

24.3.3.5. Analyst commentary

24.3.4. Fujifilm Diosynth Biotechnologies (FUJIFILM Holdings)

24.3.4.1. Overview

24.3.4.2. Product Portfolio

24.3.4.3. Key Financial

24.3.4.4. Sales Footprint

24.3.4.5. Analyst commentary

24.3.5. AbbVie Contract Manufacturing (AbbVie Inc.)

24.3.5.1. Overview

24.3.5.2. Product Portfolio

24.3.5.3. Key Financial

24.3.5.4. Sales Footprint

24.3.5.5. Analyst commentary

24.3.6. WuXi Biologics (Cayman) Inc.

24.3.6.1. Overview

24.3.6.2. Product Portfolio

24.3.6.3. Key Financial

24.3.6.4. Sales Footprint

24.3.6.5. Analyst commentary

24.3.7. Patheon N.V. (Thermo Fisher Scientific Inc.)

24.3.7.1. Overview

24.3.7.2. Product Portfolio

24.3.7.3. Key Financial

24.3.7.4. Sales Footprint

24.3.7.5. Analyst commentary

24.3.8. Emergent BioSolutions Inc.

24.3.8.1. Overview

24.3.8.2. Product Portfolio

24.3.8.3. Key Financial

24.3.8.4. Sales Footprint

24.3.8.5. Analyst commentary

24.3.9. AGC Biologics

24.3.9.1. Overview

24.3.9.2. Product Portfolio

24.3.9.3. Key Financial

24.3.9.4. Sales Footprint

24.3.9.5. Analyst commentary

24.3.10. Ajinomoto Bio-Pharma (Ajinomoto Co., Inc.)

24.3.10.1. Overview

24.3.10.2. Product Portfolio

24.3.10.3. Key Financial

24.3.10.4. Sales Footprint

24.3.10.5. Analyst commentary

24.3.11. Avid Bioservices, Inc.

24.3.11.1. Overview

24.3.11.2. Product Portfolio

24.3.11.3. Key Financial

24.3.11.4. Sales Footprint

24.3.11.5. Analyst commentary

24.3.12. KBI Biopharma (JSR Life Sciences (JLS))

24.3.12.1. Overview

24.3.12.2. Product Portfolio

24.3.12.3. Key Financial

24.3.12.4. Sales Footprint

24.3.12.5. Analyst commentary

24.3.13. Catalent Inc.

24.3.13.1. Overview

24.3.13.2. Product Portfolio

24.3.13.3. Key Financial

24.3.13.4. Sales Footprint

24.3.13.5. Analyst commentary

24.3.14. Abzena Plc.

24.3.14.1. Overview

24.3.14.2. Product Portfolio

24.3.14.3. Key Financial

24.3.14.4. Sales Footprint

24.3.14.5. Analyst commentary

25. Assumptions and Acronyms Used

26. Research Methodology

Table 01: Global Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Product

Table 02: Global Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Product

Table 03: Global Biologics Contract Manufacturing Demand Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Product

Table 04: Global Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Platform

Table 05: Global Biologics Contract Manufacturing Demand Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Platform

Table 06: Global Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Therapeutic Area

Table 07: Global Biologics Contract Manufacturing Demand Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Therapeutic Area

Table 08: Global Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Application

Table 09: Global Biologics Contract Manufacturing Demand Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Application

Table 10: Global Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Region

Table 11: Global Biologics Contract Manufacturing Demand Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Region

Table 12: North America Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Country

Table 13: North America Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Product

Table 14: North America Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Platform

Table 15: North America Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Therapeutic Area

Table 16: North America Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Application

Table 17: Latin America Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Product

Table 18: Latin America Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Platform

Table 19: Latin America Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Therapeutic Area

Table 20: Latin America Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Application

Table 21: Europe Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Country

Table 22: Europe Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Product

Table 23: Europe Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Platform

Table 24: Europe Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Therapeutic Area

Table 25: Europe Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Application

Table 26: South Asia Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Country

Table 27: South Asia Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Product

Table 28: South Asia Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Platform

Table 29: South Asia Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Therapeutic Area

Table 30: South Asia Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Application

Table 31: East Asia Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Country

Table 32: East Asia Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Product

Table 33: East Asia Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Platform

Table 34: East Asia Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Therapeutic Area

Table 35: East Asia Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Application

Table 36: Oceania Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Country

Table 37: Oceania Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Product

Table 38: Oceania Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Platform

Table 39: Oceania Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Therapeutic Area

Table 40: Oceania Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Application

Table 41: Middle East & Africa (MEA) Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Country

Table 42: Middle East & Africa (MEA) Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Product

Table 43: Middle East & Africa (MEA) Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Platform

Table 44: Middle East & Africa (MEA) Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Therapeutic Area

Table 45: Middle East & Africa (MEA) Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Application

Table 46: U. S. Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Product

Table 47: U. S. Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Platform

Table 48: U. S. Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Therapeutic Area

Table 49: U. S. Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Application

Table 50: Canada Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Product

Table 51: Canada Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Platform

Table 52: Canada Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Therapeutic Area

Table 53: Canada Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Application

Table 54: U. K. Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Product

Table 55: U. K. Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Platform

Table 56: U. K. Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Therapeutic Area

Table 57: U. K. Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Application

Table 58: Germany Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Product

Table 59: Germany Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Platform

Table 60: Germany Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Therapeutic Area

Table 61: Germany Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Application

Table 62: France Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Product

Table 63: France Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Platform

Table 64: France Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Therapeutic Area

Table 65: France Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Application

Table 66: Spain Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Product

Table 67: Spain Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Platform

Table 68: Spain Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Therapeutic Area

Table 69: Spain Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Application

Table 70: Italy Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Product

Table 71: Italy Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Platform

Table 72: Italy Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Therapeutic Area

Table 73: Italy Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Application